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Abstract:
Genes encoding B lineage restricted transcription factors are frequently mutated in B-lymphoid
leukemias, suggesting a close link between normal and malignant B-cell development. One of these
transcription factors is Early B cell Factor 1 (EBF1), a protein of critical importance for lineage
specification and survival of B-lymphoid progenitors. Here, we report that impaired EBF1 function in
mouse B-cell progenitors results in reduced expression of Myc. Ectopic expression of MYC partially
rescued B-cell expansion in the absence of EBF1 both in vivo and in vitro. Using chromosome conformation
analysis in combination with ATAC-seq, ChIP-seq and reporter gene assays, we identified six EBF
responsive enhancer elements within the Myc locus. CRISPR-Cas9 mediated targeting of EBF1 binding sites
identified one element of key importance for Myc expression and pro-B cell expansion. These data provide
evidence that Myc is a direct target of EBF1. Furthermore, ChIP-seq analysis revealed that several
regulatory elements in the Myc locus are targets of PAX5. However, ectopic expression of PAX5 in EBF1
deficient cells inhibits the cell cycle and reduces Myc expression, suggesting that EBF1 and PAX5 act in
an opposing manner to regulate Myc levels. This hypothesis is further substantiated by the finding that
Pax5 inactivation reduces requirements for EBF1 in pro-B cell expansion. The binding of EBF1 and PAX5 to
regulatory elements in the human MYC gene in a B-ALL cell line indicate that the EBF1:PAX5:MYC
regulatory loop is conserved and may control both normal and malignant B-cell development.
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Abstract: 
Genes encoding B lineage restricted transcription factors are frequently mutated in B-lymphoid 
leukemias, suggesting a close link between normal and malignant B-cell development. One of 
these transcription factors is Early B cell Factor 1 (EBF1), a protein of critical importance for 
lineage specification and survival of B-lymphoid progenitors. Here, we report that impaired EBF1 
function in mouse B-cell progenitors results in reduced expression of Myc. Ectopic expression of 
MYC partially rescued B-cell expansion in the absence of EBF1 both in vivo and in vitro. Using 
chromosome conformation analysis in combination with ATAC-seq, ChIP-seq and reporter gene 
assays, we identified six EBF responsive enhancer elements within the Myc locus. CRISPR-Cas9 
mediated targeting of EBF1 binding sites identified one element of key importance for Myc 
expression and pro-B cell expansion. These data provide evidence that Myc is a direct target of 
EBF1. Furthermore, ChIP-seq analysis revealed that several regulatory elements in the Myc locus 
are targets of PAX5. However, ectopic expression of PAX5 in EBF1 deficient cells inhibits the 
cell cycle and reduces Myc expression, suggesting that EBF1 and PAX5 act in an opposing manner 
to regulate Myc levels. This hypothesis is further substantiated by the finding that Pax5 
inactivation reduces requirements for EBF1 in pro-B cell expansion. The binding of EBF1 and 
PAX5 to regulatory elements in the human MYC gene in a B-ALL cell line indicate that the 









Main point #1: The Myc gene is a direct and essential target of EBF1 in early B-lymphocyte 
development in mice. 
Main point #2: EBF1, PAX5 and MYC create a functional loop that control normal pro-B cell 
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Introduction. 
The formation of lineage restricted progenitor cells during hematopoiesis is under stringent control 
of transcription factor networks. This is well documented in B-lymphocyte development, where 
the coordinated action of factors including TCF3, IKZF1, EBF1 and PAX5 control specification 
as well as lineage restriction 1. Although the developmental arrest observed in B-cell acute 
lymphoblastic leukemia (B-ALL) cells establishes a link between development and disease, the 
finding that several regulators of normal B-cell development are targeted by mutations in 
malignant cells 2-5 suggests a direct role of transcription factor networks in transformation 6. These 
genetic alterations include inactivating mutations in the transcription factors IKZF1, EBF1 and 
PAX5 2-5, which are all independently critical for progression of normal B-cell development 6. 
Because these transcription factors are essential for normal differentiation, it has been suggested 
that their reduced functional activities contribute to the developmental arrest observed in B-ALL 
3-5. Support for this idea comes from the finding that re-expression of PAX5 in a leukemia model 
is sufficient to release the developmental block of the transformed cells 7.  However, leukemia 
developed more efficiently in mouse models where one allele of Ebf1 or Pax5 was inactivated, 
versus a complete developmental block introduced by homozygous mutation of Rag1 or Igµ 8. 
These observations suggest that EBF1 and PAX5 may have more complex roles in the 
transformation process including control of DNA repair 9 and metabolism 10. While both PAX5 
and IKZF1 act as repressors of metabolism in B-cell progenitors 10, was been reported that EBF1 
is critical for cell survival and proliferation in these cells 11-13. Inactivation of the Ebf1 gene in pro-
B cells results in the rapid loss of progenitor cells in vivo that can only be overcome by malignant 
transformation or, to some extent, by ectopic expression of BCL2L1 or MYB 13. Together, these 
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data suggest that EBF1 and PAX5 have distinct and possibly opposing functions in the regulation 
of cell survival and proliferation in normal B-cell development.  
 
Here, we report that loss of functional EBF1 results in reduced expression of the Myc proto-
oncogene (c-Myc) in B-cell progenitors. Our identification of six distinct EBF1 responsive 
regulatory elements annotated to the Myc gene either by proximity or Proximity Ligated 
Associated ChIP (PLAC)-seq analysis suggest that Myc is a direct target of EBF1 in developing 
B-cells. Ectopic expression of PAX5 in the absence of functional EBF1 causes partial cell cycle 
arrest and reduced Myc expression supporting the idea that pro-B-cell expansion depends on the 
opposing effects of EBF1 and PAX5 on the regulation of the Myc gene. Our identification of EBF1 
and PAX5 binding regions in the human MYC locus defines a potential mechanisms for how 
disruption of this regulatory loop may contribute to malignant conversion of B cell progenitors to 
cause B-ALL.  
 
Methods: 
All animal experiments were performed with the consent of the ethical boards at Linköping and 
Lund Universities.  
For details of experimental procedures please see Supplementary Materials and Methods.  
Sequencing data is deposited in GEO as: GSE136238 (Figure S1, Supplementary data sheets) and 
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Results: 
EBF1 is essential for normal cell expansion in early progenitor cells. 
To explore the molecular mechanism by which EBF1 regulates cell survival and proliferation, we 
utilized a model system based on a 4-Hydroxytamoxifen (4-OHT) responsive EBF1 protein 
(EBF1-ER) 14 expressed in B-cell progenitors from Ebf1-/- mice 15. This system allows us to 
dynamically control the function of EBF1 by regulating its nuclear accessibility 14. Infection of 
bone marrow (BM) cells from neonatal mice or fetal liver (FL) progenitor cells with retroviruses 
encoding either a conventional EBF1 or 4-OHT responsive EBF1-ER protein allowed for the 
formation of CD19+ pro-B cells on OP9 stroma cells in the presence of 4-OHT (Figure 1A). 
Withdrawal of 4-OHT for 72 hours did not result in any significant reduction in live cell recovery 
of cells rescued by expression of conventional EBF1 (Figure S1A). However,  CD19+ cells 
generated by expression of EBF1-ER rapidly responded to removal of 4-OHT by reduced growth 
and loss of live cells (Figure 1B, S1B). To explore the viability of the cells remaining after 72 
hours, we re-plated 10 or 50 live cells on OP9 stroma cells in the presence of 4-OHT. This revealed 
significantly reduced cloning frequencies of cells pre-incubated in the absence of 4-OHT. Thus, 
live cells remaining after EBF1 depletion, display an irreversible defect in cellular expansion 
(Figure S1C). Determination of the cell cycle status of EBF1-ER transduced cells 48 hours after 
removal of 4-OHT revealed an increased portion of cells in the G0 stage and a relative reduction 
of cells in G1, S, G2 and M-phase in the absence as compared to the presence of 4-OHT (Figure 
1C). Hence, depletion of nuclear EBF1 results in a partial cell cycle arrest with the majority of 
cells exiting the cell cycle to reside in G0.  
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The role of EBF1 in pro-B cell expansion was further investigated by transplantation of 
CD19+CD45.2+ Ebf1-/- cells, rescued by expression of either conventional EBF1 or ER-fused 
EBF1 by cultivation in 4-OHT, into congenic mice (Figure 1D). While CD19+CD45.2+ cells 
expressing conventional EBF1 were detected three weeks after transplantation, few CD45.2 cells 
were found in the BM of mice transplanted with CD19+ cells rescued in vitro by expression of the 
EBF1-ER protein (Figure 1E-F). These data support the idea that EBF1 is essential for normal pro-
B cell expansion 11-13.  
 
To resolve the molecular mechanisms underlying the role of EBF1 in pro/pre-B cell expansion, 
we used RNA-seq to identify genes with altered expression patterns 72 hours after 4-OHT removal 
from Ebf1-/- EBF1-ER rescued cells. EBF1 expressing cells cultivated either in the presence or 
absence of 4-OHT were used as a control to identify and exclude drug induced changes in gene 
expression patterns (Supplementary dataset sheet 1,2, Figure S1D). While mRNA levels from 
EBF1 target genes such as Igll1, Vpreb3 and Vpreb2 were reduced upon loss of nuclear EBF1, 
Pax5 expression was modestly altered (Figure S1D, Figure 1G, Supplementary dataset sheet 1, 2). 
We did not detect dramatically reduced levels of the proposed EBF1 targets Myb (1.2-fold 
downregulated) or Bcl2l1 (1.2-fold upregulated)13. Furthermore, we were unable to detect any 
significant reduction in the levels of phosphorylated STAT5 in the EBF1-ER transduced cells upon 
removal of 4-OHT (Figure S1E, F). Hence, we do not find support for that the short-term loss of 
nuclear EBF1 result in collapse of the lineage-specific transcriptional program or dysfunctional 
IL7 signaling. In contrast, we detected significantly reduced expression of Myc by RNA-seq 
(Figure S1D) as well as RT-Q-PCR (Figure 1G).  
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MYC has been reported to be essential for normal B-cell development 16,17, and Myc expressing 
tumors have been reported to tolerate loss of EBF1 expression 18. These observations indicate the 
existence of a functional interplay between EBF1 and MYC. To investigate a potential functional 
interaction between MYC and EBF1, we transduced EBF1- or EBF1-ER-rescued Ebf1-/- CD19+ 
BM pro-B cells with a bi-cistronic MYC-RFP encoding retroviruses. Enforced expression of MYC 
had a minor impact on cell recovery in control (MIG), EBF1 or EBF1-ER virus transduced Ebf1-/- 
cells in the presence of 4-OHT (Figure 2A-C).  However, while Ebf1-/- EBF1-ER cells transduced 
with the control RFP virus expanded poorly after 4-OHT removal, Ebf1-/- EBF1-ER pro-B cells 
transduced with the MYC encoding virus did not display the same dependency on nuclear EBF1 
(Figure 2C). Furthermore, ectopic expression of MYC was sufficient for pro-B cell recovery in the 
absence of nuclear EBF1 after transplantation of EBF1-ER rescued CD19+ cells (Figure 1A) into 
congenic mice in the absence of 4-OHT treatment (Figure 2D). However, while ectopic expression 
of MYC allowed for the expansion of CD19+ cells in vivo, we did not detect generation of IgM+ 
cells in the transplanted mice (Figure 2E). The removal of 4-OHT for 48 hours increased 
frequencies of apoptotic cells selectively in the EBF1-ER expressing cells, an effect that could not 
be rescued by ectopic MYC  expression (Figure 2F). Hence, ectopic expression of MYC reduced 
requirements for EBF1 in pro-B cell expansion, but we do not find evidence for that MYC can 
prevent apoptosis or substitute for EBF1 in B-lineage differentiation.   
 
Because MYC has been suggested to be differentially expressed during the cell cycle 19, we used 
FACS to determine MYC protein levels in G0, G1, S and G2/M phase pro-B cells. Similar to 
previous observations 19,  MYC protein levels increased progressively from low levels in G0 cells 
to the highest levels in G2/M phase cells in control pro-B cells as well as in the Ebf1-/- cells 
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expressing the EBF1-ER protein (Figure 2G). The functional inactivation of EBF1 by removal of 
4-OHT resulted in an increased of the MYClow G0 fraction relative to the cells cultivated in the 
presence of 4-OHT. Furthermore, determination of the ratio of MYC protein levels in G0 cells, as 
compared with those observed in active stages of the cell cycle, revealed that the EBF1-ER 
expressing G0 cells expressed relatively lower levels of MYC as compared to actively cycling 
cells in the absence of 4-OHT (Figure 2H). While these data verify that MYC levels are reduced 
upon inactivation of EBF1, the complex relation between MYC levels and cell cycle progression 
calls for additional analysis to resolve if Myc is a direct target for EBF1 in pro-B cells. 
 
The Myc-gene is a direct target of EBF1 in pro-B cells. 
The regulation of the Myc gene is highly complex and involve regulatory elements located as far 
as 1.7 MBp from the coding sequences 20. Hence, a direct screening of the promoter or proximity 
annotated distal elements for EBF1 binding sites would not provide an exhaustive identification 
of EBF1 sites that participate in the regulation of Myc. To identify distal regions that interact with 
the Myc promoter in pro-B cells we generated Proximity Ligation Assisted ChIP (PLAC)-seq data 
from Wt and Ebf1-/- pro-B cells and carried out a virtual 4C analysis with the Myc-promoter as the 
viewpoint (Figure 3A). This revealed that the major part of the distal interacting elements, 
including the Blood Enhancer Cluster (BENC)-superenhancer region 20, was located 3´ of the Myc 
gene. Combining PLAC-seq data with ATAC-seq data generated using Wt or Ebf1-/- pro-B cells 
21,22 and analyzing these together with EBF1-ChIP-seq data from 230-238 progenitor B-cells, we 
identified multiple EBF1 binding elements in the Myc locus  (Figure 3A). Correlations between 
the datasets allowed for the identification of one region 5´ of the Myc gene (5’E) as well as five 
putative EBF1 targeted regulatory elements 3´ of the coding gene (Figure 3A, B). One of these 
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(E1) was located just over 700 kBp from the coding gene while the remaining 4 elements (E2-5) 
were located between 1.6 and 1.7 Mbp from the TSS within the region defined as harboring the 
BENC super-enhancer 20. While E4-5 displayed accessibility, as determined by ATAC-seq 
analysis, in both Wt and Ebf1-/- cells, E1-3 accessibility was limited in EBF1 deficient cells 
indicating that the epigenetic state of these elements depend on EBF1 (Figure 3B). Reanalysis of 
ChIP- and Cut&Run-seq data from fetal liver pro-B cells (GSE162858), revealed enrichment of 
acetylated histone H3 lysine K27 (H3K27ac) at the EBF1 bound regions (Figure 3B), indicating 
that they represent active elements. Further, these regions were enriched for demethylated H3 lysin 
4 (H3K4me2) while the levels of the promoter associated tri-methylated Histone H3 lysin 4 
(H3K4me3) was low (Figure 3B).  These data support the conclusion that elements bound by EBF1 
in the Myc locus are active enhancers in pro-B cells. 
 
To investigate if these elements act as EBF1 responsive enhancers, we cloned the identified regions 
into a luciferase reporter vector upstream of a basal Fos promoter. The reporter constructs were 
transfected into Hela cells, lacking expression of endogenous EBF1, together with empty or EBF1 
encoding cDNA3 vectors (Figure 3C). Each of the elements responded to the expression of EBF1 
by 4-7-fold increases in luciferase activity (Figure 3C) as compared to the 1.6-fold upregulation 
observed for of the basal Fos promoter (Figure S2A). These data confirm that the Myc locus 
harbors EBF1 responsive regulatory elements.  
 
To investigate whether EBF1 binding sites in these elements are functionally important for normal 
growth and expansion of pro-B cells we inspected the DNA sequences to identify putative binding 
sites in all the identified EBF responsive enhancers (Figure 4A). To investigate the ability of these 
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sites to interact with EBF1 we performed Electrophoretic Mobility Shift Assays (EMSA) (Figure 
4B). Binding of in vitro translated EBF1 to P32 labelled duplex oligonucleotide from the Cd79a 
promoter (Figure S2B) was competed by excess unlabeled putative binding sites from the EBF1 
responsive Myc enhancers. Binding to the Cd79a promoter EBF1 site was efficiently competed by 
putative binding regions in the Myc enhancers (Figure 4B) confirming the presence of EBF1 
binding sites in the Myc locus.  
 
Having identified EBF1 binding sites, we sought to confirm their function in pro-B cells. To this 
end we took advantage of a mouse model where the expression of Cas9 is under the regulation of 
a Tetracycline (Doxycycline) -responsive promoter. These mice were crossed to animals carrying 
a Doxycycline-dependent transcriptional activator (rTTA) under the control of the broadly active 
ROSA26 locus. We then designed guide RNAs (gRNAs) targeting several of the EBF1 binding 
sites as well as the Myc coding region. As an additional control we targeted an EBF1 binding site 
annotated to the Gfra2 gene, shown redundant for B-cell development 21. The gRNAs were cloned 
into lentiviral vector backbones expressing a red-fluorescent marker protein (mCherry). KIT+ 
primary BM cells were transduced with the gRNA virus constructs, sorted for expression of 
mCherry and differentiated in vitro into pro-B cells. Before the addition of Doxycyclin, samples 
of cells were extracted to determine the distribution of gRNAs in the input populations by PCR 
amplification of viral inserts in genomic DNA (Library 1). After Cas9 induction, the cells were 
grown for 6 days, the remaining progenitors were collected and the distribution of integrated 
gRNAs in the genomic DNA of the remaining cells was determined (Library 2). High throughput 
sequencing of the PCR products allowed us to compare the ratio of guides in the input (Library 1) 
as compared to the cells present 6 days after induction of Cas9 expression (Library 2). This 
                                                                                                      Somasundaram et al. 12
revealed a reduced representation of guides 106 and 107, both targeting the same EBF1 binding 
site in E2 (Figure S2C, 4C).  We could also detect a reduced representation of guides targeting the 
coding region of the Myc gene (111 and 112). We noted a modest increase in the relative presence 
of several guides, likely as a reflection of reduced relative presence of guide 106, 107, 111 and 
112. In order to explore the editing efficiency of our gRNAs we amplified the targeted regions in 
the total population by genomic PCR, sequenced the obtained products and determined mutation 
rates. Comparing the mutation rates of the target regions to the relative presence of inserted gRNAs 
suggested efficient editing by all the investigated guides (Figure S2D) indicating that only the 
EBF1 site in E2 is non-redundant for normal pro-B cell expansion.  
 
To verify the role of the E2 site, we transduced progenitor cells with guide RNA 106 (E2), 107 
(E2) (Figure 4C) as well as gRNA 112, targeting the Myc gene, and gRNA 81, targeting a putative 
EBF1 binding site in the Gfra2 locus.  Two days after induction of Cas9 transcription by the 
addition of Doxycyclin, Myc mRNA levels were reduced in the cells transduced with the guides 
targeting the E2-EBF1 site (sg107, Figure 4D or sg106, Figure S2E) as compared to those 
expressing sg81. Following the expansion of B-cell progenitors in vitro from 24 to 96 hours after 
the induction of Cas9 expression, we noted the reduced expansion of cells transduced with either 
guide 106, 107 or 112 as compared to those transduced with the Gfra2 locus targeting guide 81 
(Figure 2E). To determine the targeting efficiency, we extracted DNA from cells harvested 96 
hours after CAS9 induction, amplified the targeted region by PCR and sequenced the obtained 
products. All four guides facilitated mutations in over 70% of the PCR products generated from 
the target sequences (Figure S2F). Even though mutations could be detected in an area spanning 
70bp, the most commonly detected indels, representing 41% (sg106) and 46% (sg107) of the reads 
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with mutations, involved 5-7 base pairs targeting the EBF1 core binding site (Figure S2G). 
Performing a motif analysis of the targeted area identified the EBF1 binding site as well as a cryptic 
E-box, potentially capable to interact with TCF3 or TCF12, and a binding site for TBX1. As the 
E-box and the TBX1 site were located 3’ of the EBF1 core site, these were preferentially targeted 
by sg106. These data show that mutations in the EBF1 binding region of E2 reduce the expression 
of Myc and pro-B cell expansion. Although the involvement of other factors should not be 
excluded, these data support the idea that Myc is a direct target for EBF1.      
 
EBF1 and PAX5 have opposing roles in the regulation of the Myc-gene. 
Next, we wanted to understand the mechanisms by which a progenitor cell develops dependency 
on EBF1. To this end, we exposed Ebf1-/-EBF1-ER FL cells to 4-OHT for four or seven days. This 
relatively short exposure result in a mixture of CD19+ and CD19- cells in the cultures. Exposure 
to 4-OHT for four days impaired the ability of CD19– , and abolished the potential of CD19+ 
progenitor cells, to expand in the absence of 4-OHT in secondary cultures (Figure 5A). This 
suggests the rapid development of EBF1 dependency in early B-cell progenitors.  
 
Cd19 expression is linked to its transcriptional activation by PAX5, a transcription factor 
suggested to suppress Myc expression 7,23. Because the Pax5 gene is a target of EBF1 24, this 
suggests that EBF1 and PAX5 function with opposing activities in a regulatory loop controlling 
Myc expression. This idea was supported by that ectopic expression of PAX5 in Ebf1-/- cells 
resulted in reduced cell expansion and formation of CD19+ cells 4 days after transduction (Figure 
5B, C). The levels of PAX5 protein 24 hours after transduction were comparable to those observed 
in Wt cells arguing against that the observed phenotype was a result of abnormally high PAX5 
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levels enforced by the retroviral construct (Figure S3). The impact of PAX5 expression on cell 
proliferation was reflected by the accumulation of cells in G0 (Figure 5D). Determination of the 
Myc expression levels in the surviving PAX5 expressing cells by Q-RT-PCR 72 hours after virus 
transduction revealed reduced levels compared to those of EBF1 transduced cells (Figure 5E). 
Analysis of MYC protein levels as a function of cell cycle stage 48 hours after transduction with 
PAX5- or EBF1-expressing MIG virus revealed a small but significantly increased ratio of MYC 
protein in G0 versus G1 in the PAX5 transduced cells (Figure 5F).  Furthermore, RNA-seq analysis 
of PAX5 transduced Ebf1-/- cells followed by Gene Set Enrichment (GSEA) analysis (Figure 5G) 
revealed a reduction of the MYC-associated transcriptional program supporting the idea that PAX5 
functions as a negative regulator of Myc expression in normal B-cell progenitors. 
 
To study the direct role for PAX5 in the induction of EBF1 dependency, we used CRISPR-Cas9-
mediated gene targeting to inactivate the Pax5 gene in CD19+ Ebf1-/- BM cells expressing either 
EBF1 or EBF1-ER. FACS analysis of the targeted cells revealed the generation of a CD19- 
population (Figure 5H) expressing reduced levels of PAX5 (Figure 5I) upon expression of Pax5 
sgRNAs. Assessing the ability of the CD19- cells to expand in the absence of 4-OHT, we noted a 
significant increase in cell recovery of EBF1-ER rescued cells as compared to cells expressing 
normal levels of PAX5 (Figure 5J). These data, in combination with the observation that PAX5 
binds to regulatory elements in the Myc gene (Figure 3A), support that EBF1 and PAX5 create a 
regulatory loop to regulate cell proliferation in pro-B cells.  
 
Putative regulatory elements in the human MYC locus are targeted by EBF1 and PAX5 in pro-B 
ALL cells. 
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To determine whether the human MYC gene is targeted by EBF1 and/or PAX5 we took advantage 
of a combination of ChIP-seq, ATAC-seq and PLAC-seq data 22 to identify regulatory elements 
interacting with the MYC promoter in the human pre-B cell line NALM6. This analysis identified 
several distal elements displaying ATAC-accessibility and H3K27 acetylation. Several of these 
elements bound both EBF1 and PAX5 (Figure 6A) revealing that the human MYC gene is targeted 
by both proteins via several putative regulatory elements. Interestingly, this analysis also supported 
the hypothesis that the MYC gene is targeted by IKZF1 and RUNX1 (Figure 6A), which are both 
frequently mutated and generate fusion proteins in combination with PAX5 and EBF1 in human 
B-ALL 3-5. Hence, the regulatory regions of the human MYC gene may represent a hub for 
oncoprotein interaction in B-ALL.  
 
Discussion. 
Here, we report that Myc is a direct and critical target for EBF1. As MYC has been reported to be 
essential for B-cell development 16,17, our findings provide a potential explanation for the 
importance of EBF1 in normal pro-B cell survival and expansion 11-13. While the functional activity 
of MYC is regulated at multiple levels including translation, protein stability and interplay with 
interacting partners 19, our data suggest that EBF1 directly target regulatory elements in the Myc 
locus in non-transformed cells. The regulation of the MYC gene has been extensively studied due 
to the role of this protein in human malignancies 25. While MYC is broadly expressed, the mouse 
Myc locus is targeted by multiple transcription factors in different tissues, including the lineage 
restricted transcription factor GATA3 in developing T cells 26. Myc is under the influence of both 
proximal and distal control elements including the BENC-superenhancer region located 
approximately 1.7 Mbp from the coding gene 20. As several of the enhancer elements identified 
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display reduced ATAC-accessibility in EBF1 deficient cells (Figure 3B), our data support the idea 
that the BENC-region harbors several independently activated regulatory elements 20. Of note is 
that the D-element, located in the BENC-region and shown of importance for B-cell development 
20, overlap with the E4 element defined in this report. Due to the lack of suitable gRNAs we did 
not target this EBF binding site. However, even though the D-deletion spanned approximately 
1000 bp 20, these data collectively suggest the presence of two functionally important EBF binding 
regions in the BENC enhancer. The observation that mutation of any of these elements causes 
reduced cell growth (Figure 4E) suggest that despite the complexity of this enhancer cluster, there 
is limited functional redundancy. Hence, while the general idea that transcription regulatory 
circuits are stable persist 27, Myc highlight that the complex interplay between enhancer elements 
in development 28 may be modulated to fine tune transcriptional programs to create lineage specific 
regulatory modules.  
 
As the Pax5 gene is a direct target for EBF1 24, our data suggest that these proteins create a 
regulatory loop directly involved in the control of pro-B cell expansion. Furthermore, as EBF1 act 
upstream of PAX5 in B-lymphocyte development, PAX5 mediated repression of cell expansion in 
the absence of EBF1 would promote an ordered differentiation process. A direct link between 
expression of a fate determining factor such as EBF1 11,29-31 and regulation of cell survival and 
expansion may also be of importance for the preservation of lineage identity. While this would be 
important in normal development, it is notable that MYC induced B-cell lymphomas display 
lineage plasticity 32. Furthermore, cells carrying mutations in the Ebf1 and/or Pax5 genes can be 
converted into T-ALL 33 or even myeloid leukemia 34. This may be of relevance for leukemia 
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progression as lineage plasticity is emerging as a potential challenge in lineage targeted treatment 
of leukemias 34-36.  
 
Our data also provides an insight into how the dosage of lineage-determining factors impacts 
normal differentiation 37-39. We here report that a key regulator of cell proliferation (MYC) is 
subject to both positive and negative regulation by two transcription factors in the same network. 
Reduced functional dosage of PAX5 could, in this regulatory loop, cause EBF1 to drive Myc 
transcription to higher-than-normal levels (Figure 6B). The complexity of this loop may be 
extended even further because it has been reported that the mouse Ebf1 gene contains a MYC 
responsive enhancer element 16 and that that PAX5 acts as a positive regulator of N-Myc 40.  The 
frequent mutations in PAX5 2-5 could result in a disruption of the regulatory feedback loop at the 
MYC locus causing EBF1 to super-activate this gene (Figure 6B). It should, however, be noted that 
the role of EBF1 in a transformed cell appears different from that in normal cells. Requirements 
for EBF1 in pro-B cells can be circumvented by malignant transformation 13 and it has recently 
been suggested that EBF1 is a repressor of Myc transcription in a mouse model for leukemia 23. 
Despite the apparently distinct functions of EBF1 in normal and malignant cells, reanalysis of 
EBF1 Chip-seq data from normal and transformed cells 23 did not reveal any obvious differences 
in EBF1 binding at the elements defined in this report. Hence, the mechanism underlying these 
apparently opposing functions of EBF1 reside is more complex events than alterations in direct 
DNA binding at these elements.  
 
While data obtained in mouse models should be extrapolated to human disease with great care, our 
data suggest that the MYC gene may be targeted by several of the key regulators of normal and 
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malignant B-cell development in humans (Figure 6A). Considering the critical role of MYC in the 
control of metabolism, cell survival and proliferation in normal and malignant cells 19,41, resolution 
of the functional interplay between key transcription factors at this locus will likely provide 
additional insights into the basic mechanisms of neoplastic transformation.  
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Figure Legends 
Figure 1: Loss of functional EBF1 results in reduced levels of Myc-transcripts and cell cycle 
arrest in pro-B cells.  
(A) Schematic drawing of the basic experimental layout. Neonatal Ebf1-/- BM or Ebf1-/- FL were 
transduced with EBF1-MIG (EBF1) or an EBF1-estrogen receptor fusion protein (EBF1-ER) 
construct. Cells were then exposed to 4-Hydroxytamoxifen (4-OHT) to allow nuclear translocation 
of EBF1 in Ebf1-deficient cells carrying the EBF1-ER construct which drives develop into the 
CD19+ stage. 4-OHT was then withdrawn to test the dependency of EBF1 in the generated CD19+ 
cells. (B) Number of live cells of cultured EBF1 or EBF1-ER transduced and 4-OHT treated Ebf1-
/- BM cell cultures (as in A panel). Cells were either incubated continuously with 4-OHT (+4-
OHT) or with 4-OHT withdrawn (-4-OHT) for 48-72 hours as indicated. Mean and SD are shown, 
n=4, from 4 culture experiments). (C) Cell cycle distributions of the cells in B at 48 hours post 4-
OHT withdrawal (mean and SEM are shown, n=6). (D) The experimental protocol used to test the 
cell autonomous role of EBF1 in pro-B cell survival in vivo. Ebf1-/- FL cells were transduced to 
express EBF1 or EBF1-ER and treated with 4-OHT for 14 days. At day 15, 1 million GFP+CD19+ 
cells were transplanted into C57BSJL (CD45.1) sub-lethally irradiated recipients. Donor 
reconstitution (CD45.2+GFP+) as well as CD19 expression was determined by FACS 3 weeks post 
transplantation.  (E, F) Relative cell counts, from the BM of mice transplanted with either EBF1 
or EBF1-ER transduced cells. Mean and SD are shown, EBF1 n=8, EBF1-ER n=11, from 2 
independent experiments. Panel (G) display diagrams with Q-RT-PCR data from in vitro expanded 
Ebf1-/- fetal liver pro-B control cells (FL) or BM cells from EBF1-deficient mice driven to B-cell 
progenitor stages with conventional or ER-fused EBF1 protein cultured in the presence or absence 
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of 4-OHT for 72 hours (mean and SD are shown, n=4-7, from 2 independent experiments). For C, 
E-G each dot indicates a datapoint and the statistical analysis is based on Student’s unpaired t-test. 
* p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
 
Figure 2: Ectopic expression of MYC rescues pro-B cell expansion in the absence of EBF1.   
Panel (A-C) display cell recovery from cultures of FL Ebf1-/- cells in vitro cultivated as described 
in Figure 1A. Cells were transduced with (A) an empty MIG-GFP (MIGR1) vector, (B) an EBF1-
GFP vector (EBF1) or (C) an ER-fused EBF1 protein (EBF1-ER) and serially transduced with an 
RFP control or a MYC expressing RFP retrovirus. The diagrams display cell recovery when the 
cells were grown in the presence or absence of 4-OHT for 72 hours (mean and SD are shown, n=6-
12, from 3 independent experiments).  (D) Recovery of CD45.2+CD19+GFP+RFP+ BM cells 3-4 
weeks after transplantation of Ebf1-/- FL pro-B cells transduced with EBF1-ER and either a control 
RFP or MYC expressing RFP encoding retrovirus into sub-lethally irradiated CD45.1 mice. Mean 
and SD are shown, n=4-6 transplanted mice. (E) Representative FACS plot of IgM and CD19 
expression on recipient (CD45.1) and donor (CD45.2+GFP+RFP+) cells. (F) Fraction of early 
(Annexin5+DAPI- (Black bar)) and late (Annexin5+DAPI+ (White bar)) apoptotic cells 48 hours 
after removal of 4-OHT in EBF1 and EBF1-ER expressing Ebf1-/- BM cells transduced with either 
RFP-control or RFP-Myc virus. Mean and SEM are shown (n=3). The statistical analysis is based 
on comparisons of data from cells grown in the presence or absence of 4-OHT. (G) Histograms 
displaying overlays of a FACS staining of MYC protein in different stages of the cell cycle and 
(H) bars depicting the ratios of MYC Median Fluorescent Intensity (MFI) of each stage of the cell 
cycle compared to G0 48 hours after 4-OHT withdrawal in Wt and Ebf1-/-EBF1-ER BM cells (mean 
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and SEM are shown, n=6). The statistical analysis is based on Student’s unpaired t-test. * p<0.05, 
** p<0.01, *** p<0.001 and **** p<0.0001. 
 
Figure 3: The mouse Myc gene contains multiple EBF1 responsive enhancer elements.   
 (A) UCSC Genome Browser view of the murine Myc locus and its distal interacting regions. The 
tracks display PAX5 (GSE126375) and EBF1 binding in 230-238 progenitor B cells, ATAC-
accessibility (GSE92434), as well as a PLAC-seq derived virtual 4C tracks from Wt and Ebf1-/- FL 
derived pro-B-cells. Myc transcriptional start site (TSS)   2.5kb were used as viewpoint for the 
virtual 4C analysis. The previously defined BENC-enhancer region 20 is indicated by a dashed 
square. (B) Zoomed in view of three specific regions in (A) with high PAX5 and EBF1 binding as 
well as ATAC-accessibility in Wt pro-B cells and interaction with the Myc promoter. These regions 
were examined for the presence of histone modifications by reanalysis of ChIP and Cut&Run seq 
data (GSE162858). The gray lines indicate the regions that are targeted for luciferase reporter 
activity assays. (C) Relative Firefly/Renilla (Prl0) luciferase activity obtained from reporter 
constructs where the EBF1 binding regions described in (B) was cloned upstream of a basal Fos 
promoter in the absence (empty cDNA3) or presence of EBF1 in HeLa cells. Each dot represents 
one transfection and the statistical analysis is based on Student’s unpaired t-test. * p<0.05, ** 
p<0.01, *** p<0.001 and **** p<0.0001.  
 
Figure 4: EBF1 directly target an essential binding site in the BENC-enhancer region.  
(A) The sequence of known EBF binding sites and six predicted EBF1 binding sites within five 
putative Myc 3´enhancer elements as well as a potential EBF1 binding site in the 5’ region of Myc. 
The core binding site is indicated by a red box (B) Autoradiogram displaying the result of an 
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EMSA experiment in which the binding of in vitro translated EBF1 to a radioactive labelled Cd79a 
promoter-EBF1 site is competed for by the addition of a 200-fold excess of non-labelled putative 
EBF1 binding sites in Myc enhancers or the PAX5 binding site from the Cd19 promoter. The 
autoradiogram is representative of two independent experiments. (C) Schematic drawing of the 
targeting of CRISPR guides 106 and 107 to the EBF1 binding site in Myc E2. The DNA sequence 
of the EBF1 binding motif is depicted in yellow and guides 106 (light brown) and 107 (dark brown) 
are shown pointing towards a 3’ NGG PAM sequence. The scale indicates the genomic location 
on mouse chromosome 15. (D) Myc Q-RT-PCR data from CD19+ iCas9 BM cells transduced with 
CRISPR guide 81 (control) or 107 (Myc E2) and subsequently treated with DOX for 48 hours 
(mean and SD shown, n=6, from 3 individual samples from different mice). (E) Proliferation per 
100 iCas9 CD19+ BM cells at 24, 48 and 96 hours after DOX administration in samples infected 
with gRNA constructs sg106 and 107 (targeting EBF1 binding site Myc E2), sg81 (targeting an 
EBF1 site linked to the Gfra2 gene) or sg112 (targeting the coding region of Myc). Mean and SD 
are shown, P * < 0.05, ** < 0.01 (Student’s t test compared to sg81), from 3 independent samples 
from different mice.   
 
Figure 5: PAX5 act as a negative regulator of cell proliferation and MYC function in pro-B 
cells. 
(A) Cell recovery 3 days after seeding of 2000 sorted GFP+CD45+ in vitro expanded FL cells from 
Ebf1-/- mice exposed to nuclear EBF1 by cultivation in 4-OHT for 4 or 7 days before sorting and 
reseeding in cultures in the absence of 4-OHT (mean and SD are shown, n=5-6, from 2 
independent experiments). (B) Total cell recovery and (C) the fraction of CD19+ cells recovered 
4 days after seeding 2000 GFP+ Ebf1-/- FL cells transduced with either MIG-control, EBF1 or 
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PAX5 encoding virus (mean and SD are shown, n=7, from 2 independent experiments). (D) Cell 
cycle data from Ebf1-/- FL cells transduced with MIG-control, EBF1 or PAX5 encoding virus as 
determined by FACS analysis (mean and SEM are shown, n=3). (E) Q-RT-PCR analysis 
determining the levels of Myc transcripts in live sorted Wt FL cells or transduced EBF1 deficient 
cells as in panel B. Mean and SD are shown, n=4, from 4 samples. (F) The ratio of MYC MFI of 
each stage of the cell cycle compared to G0 in Ebf1-deficient cells transduced with EBF1 or PAX5 
encoding vectors (mean and SEM, n=3). (G) GSEA of genes in 
HALLMARK_MYC_TARGET_V1 gene set based on RPKM normalized RNA-seq data from 
Ebf1-/- FL cells transduced with a control GFP or PAX5 encoding virus. FDR = False Discovery 
Rate, NES = Normalized Enrichment Score. (H) Representative histograms of Ebf1-/- bone 
marrow cells rescued to the CD19+ pro-B cell stage by transduction with either a conventional or 
ER-fused EBF1 encoding retrovirus and transduced with a Cas9 encoding virus alone or in 
combination with a Pax5 targeting gRNA and (I) MFI values for PAX5 levels as determined by 
flow cytometry (mean and SD, n=4, from 4 individual samples). (J) Cell recovery after 3 days of 
in vitro culture of EBF1 or EBF1-ER transduced cells expressing Cas9 alone or Cas9 in 
combination with gRNAs targeted to the Pax5 gene (gPAX5) (mean and SD, n=4, from 4 
individual samples).  For A-E, I-J each dot indicates a datapoint and the statistical analysis are 
based on Student’s unpaired t-test. * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001.  
 
Figure 6: Putative regulatory elements in the human MYC gene is targeted by EBF1 and 
PAX5 in pro-B ALL cells. 
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(A) ChIP-seq, ATAC-seq and PLAC-seq tracks for the human MYC (c-MYC) gene displayed in 
WashU Epigenome Browser. Data were re-analyzed from 22 (GSE126300). (B) Schematic drawing 
of a model for regulatory loops controlling Myc expression in development. 
 
 






